Skip to content
contact@indiamedicine.orgLogin / Register
IMSDA
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
Search for:
Menu Close
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us

Blog

  1. Home>
  2. News>
  3. PAXLOVID – CONDITIONS OF USE

PAXLOVID – CONDITIONS OF USE

  • Post published:December 16, 2022
  • Post category:News
paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-conditions-use-conditions-distribution_enDownload

MEDICINAL PRODUCT FOR USE

1. Name of the medicinal product for use: PAXLOVID

2. Active substance(s): Nirmatrelvir and ritonavir

3. Pharmaceutical form: Film-coated tablets

4. Route of administration: Oral use

5. Strength: 150 mg Nirmatrelvir , 100 mg ritonavir

Please Share This Share this content

  • Opens in a new window Twitter
  • Opens in a new window Facebook
  • Opens in a new window Google+
  • Opens in a new window Pinterest
  • Opens in a new window LinkedIn
  • Opens in a new window Viber
  • Opens in a new window VK
  • Opens in a new window Reddit
  • Opens in a new window Tumblr
  • Opens in a new window Viadeo
  • Opens in a new window WhatsApp

You Might Also Like

COVID19’s cytokine storm ushers in a local complement storm in the lungs

April 12, 2021

Researchers uncover the mysteries of sleep disorders in multiple system atrophy

April 9, 2021

Latest HIV Treatment Advances and Global Response Challenges (2025)

December 1, 2025

Recent Posts

  • How to Buy Generic Medicines Online Safely: A Consumer Guide to Verified Sources
    May 19, 2026/
    0 Comments
  • WHO Adds GLP-1 Drugs and New Cancer Treatments to Essential Medicines List in 2025 Update
    May 18, 2026/
    0 Comments
  • Indian Pharma Exports Surge 18% in Q1 FY2026-27: US ANDA Approvals & Africa Demand Drive Growth
    May 18, 2026/
    0 Comments

Follow Us

IMSDA

Recent Posts

  • How to Buy Generic Medicines Online Safely: A Consumer Guide to Verified Sources
  • WHO Adds GLP-1 Drugs and New Cancer Treatments to Essential Medicines List in 2025 Update
  • Indian Pharma Exports Surge 18% in Q1 FY2026-27: US ANDA Approvals & Africa Demand Drive Growth
  • How Indian Generic Medicines Meet Global Quality Standards: WHO-GMP, USFDA & CDSCO Explained
  • Indian Generic Pharma Exports Surge 14% in Q1 2026 as New PLI Scheme Targets 25 Additional API Molecules

Contact Info

  • If you want to touch more medicine sales and distribution resources, you could contact us, or join us.
  • Address:2nd Floor, Bhavani CHS, Dadar West, Mumbai, 400028, Maharashtra.
  • Phone:+91 8048111688
  • Email:contact@indiamedicine.orgOpens in your application
  • Website:https://indiamedicine.org/
  • Home
  • About Us
  • Drugs
  • News
  • Knowledge
  • Members
  • Contact Us
© Copyright All Right Reserve